Sudeep Pharma IPO
Sudeep Pharma IPO — date, price band, lot size & details 2025
Sudeep Pharma listed on 28 Nov 2025 at ₹730, 23.1% above the ₹593 issue price.
**Sudeep Pharma** IPO is attracting good interest from investors. The company is engaged in manufacturing and supplying pharmaceutical excipients and specialty chemicals used in medicines and healthcare products. It has a strong presence in both domestic and export markets. The IPO aims to raise funds for business expansion, working capital needs, and strengthening its market position. Investors are watching the issue considering its growth potential and industry demand.
Stock price
Sudeep Pharma is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 October.
- Open 21 Nov 2025
- Close 25 Nov 2025
- Allotment 26 Nov 2025
- Refund/credit 27 Nov 2025
- Listing 28 Nov 2025
Issue summary
The terms of the offer, as filed.
| IPO Dates | 21 to 25 Nov, 2025 |
|---|---|
| Price Band | ₹563 – ₹593 |
| Face Value | ₹1 |
| Lot Size | 25 Shares |
| Issue Size | ₹895 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | BSE & NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,825 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 25 shares at the ₹593 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 25 | ₹14,825 |
| Retail (max) | 13 | 325 | ₹1,92,725 |
| S-HNI (min) | 14 | 350 | ₹2,07,550 |
| S-HNI (max) | 67 | 1,675 | ₹9,93,275 |
| B-HNI (min) | 68 | 1,700 | ₹10,08,100 |
Three years of numbers
All figures in ₹ crore, as reported in the Sudeep Pharma offer document.
| Metric | 31 Mar 24 | 31 Mar 23 | 31 Mar 22 |
|---|---|---|---|
| Revenue | 565.55 | 959.21 | 475.51 |
| OPM % | 7.65 | ||
| EBITDA | 84.11 | 107.97 | 57.82 |
| Net Profit | -16.98 | -102.35 | -71.70 |
| Debt | 533.51 | 437.06 | 384.79 |
| Assets | 2,134.35 | 1,859.84 | 1,863.50 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Sudeep Pharma RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Sudeep Pharma IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹11.07 |
| P/E Ratio (x) | 53.55 |
| Market Cap at Offer Price (₹ Cr) | ₹-909.59 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹593 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹88.48 Cr of the issue is earmarked to named objects.
About the company
The company primarily manufactures calcium-based and mineral ingredients such as calcium carbonate, calcium citrate, and other specialty compounds widely used in tablets, dietary supplements, and fortified food products. Its business model is largely B2B, supplying to pharmaceutical companies, nutraceutical brands, and global distributors. By focusing on quality certifications, scalable manufacturing, and long-term client relationships, the company aims to sustain growth and expand its footprint in regulated and semi-regulated markets worldwide.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
+91 265 284 0656
The bankers & the filings
Who is running the book, and the documents this page is built from.
Sudeep Pharma IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
ICICI Securities
23 issues handledBest listing: Tempsens Instruments (India) (+111.3%). Weakest: Turtlemint Fintech Solutions (-10.4%).
IIFL Capital Services Limited
32 issues handledBest listing: Orient Cables (India) (+65.4%). Weakest: Acevector (-11.5%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Sudeep Pharma?
The current Grey Market Premium is ₹0.
What is the Sudeep Pharma IPO price band?
₹563 to ₹593, on a face value of ₹1.
When is the allotment?
The basis of allotment is 26 November 2025, with listing on 28 November 2025.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
